Aprea Therapeutics (APRE) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Aprea Therapeutics Inc (APRE) Prix de l'Action, Cotation, Actualités et Historique

APRENASDAQ

Trade with Public

Trade with Public

$0.5842

-0.0334-5.41%

Dern. MÀJ: Oct 16, 4:42 PM

$0.6206

0.0030.49%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

$0.66

Clôture

$0.58

Volume / Moy.

160.10K / 277.15K

Fourchette Journalière

$0.57 - $0.66

Plage 52 Sem.

0.55 - 1.69

Capitalisation Boursière

$7.81M

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

34

Intérêt à Découvert

4.29%

Jours pour Couvrir

2.45

Actualités Récentes de Aprea Therapeutics Inc

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts view APRE, SRFM, CNH stocks.

Avi Kapoor

Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.

Vandana Singh

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.

Vandana Singh

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Why Aprea Therapeutics Shares Hit A New 52-Week Low Today

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else?

Henry Khederian

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-12.17M

Flux de Trésorerie d'Investissement (TTM)

-15.40K

Flux de Trésorerie de Financement (TTM)

36.89M

Flux de Trésorerie Libre (TTM)

-12.18M

Dépenses en Capital (TTM)

-

Variation Nette de la Trésorerie (TTM)

24.70M

Tendances et prévisions des analystes

2

mai

1

août

1

oct.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

4.3

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

-$33.73M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

-

Ratio P/B (TTM)

0.20

Rendement des Bénéfices % (TTM)

-150.38%

Rendement des Bénéfices % (FWD)

-52.79%

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

$3.06

Dette Entreprise

Dette Totale

-

Dette à Long Terme

-

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-

Trésorerie Totale

$41.23M

Dette sur Capitaux Propres

-

Émission de Dette (TTM)

-

Remboursement de la Dette (TTM)

-